Orion Oyj (OTCMKTS:ORINY) Hits New 12-Month Low at $17.50

Orion Oyj (OTCMKTS:ORINY) shares hit a new 52-week low on Monday . The stock traded as low as $17.50 and last traded at $17.50, with a volume of 59 shares. The stock had previously closed at $17.50.

Orion Oyj Stock Performance

The stock has a market capitalization of $4.94 billion, a price-to-earnings ratio of 20.83 and a beta of 0.23. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 3.10. The firm has a fifty day moving average of $19.34 and a 200-day moving average of $20.23.

Orion Oyj (OTCMKTS:ORINY) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $0.29 earnings per share (EPS) for the quarter. The firm had revenue of $345.76 million during the quarter. Orion Oyj had a return on equity of 27.75% and a net margin of 18.21%. As a group, equities analysts predict that Orion Oyj will post 0.89 earnings per share for the current fiscal year.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.